Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic’s many resources and see jobs available for medical professionals. Get updates.
Philanthropy at Mayo ClinicYour support accelerates powerful innovations in patient care, research and education. Give today.
Researchers are studying vector targeting and vector detargeting to improve the pharmacology of both adenovirus and adeno-associated virus vectors for muscle gene therapy. The team is currently focused on expressing dysferlin for dysferlinopathies.
Dr. Barry and his team are developing metabolic biotinylation technologies that target any cell type using one or more vector platforms.
Researchers in the lab are studying how modified vectors fail, how the affinity of the ligands affects this process and how one might use or avoid this biology to maximize vector specificity.
Dr. Barry and the team are using metabolic biotinylated vector technology to prescreen ligands on various targeting models.
The team is studying capsomers and applying cryo-electron microscopy (cryo-EM) tags to better understand the biology of native and engineered cell-targeting viruses.
The team is directing ligand and vector targeting efforts against several cell targets, selected for distinct biological and pharmacological issues.
The lab is testing approaches to maximize antigen delivery to mucosal surfaces and developing mucosal vaccines against HIV-1, influenza and bioweapons.
The team is studying specific oncolytic adenoviruses targeting breast cancer, chronic lymphocytic leukemia, myeloma and cancer stem cells.
The team is testing polyethylene glycol and other polymers for their shielding and protective functions for liver gene therapy, for cancer therapy and during vaccination.
Researchers in the lab are applying optical imaging approaches that can be utilized for gene therapy, vaccine and cancer projects.
Mayo Clinic is a not-for-profit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.